<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001715</url>
  </required_header>
  <id_info>
    <org_study_id>ACT11308</org_study_id>
    <nct_id>NCT01001715</nct_id>
  </id_info>
  <brief_title>Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Vertebral Fracture Associated With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain
      associated with vertebral fracture.

      Secondary objectives were:

        -  to assess the safety and tolerability of REGN475/SAR164877 in patients with vertebral
           fracture pain;

        -  to characterize the pharmacokinetic and immunogenicity profiles of REGN475/SAR164877 in
           this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study period for each participant was up to 13 weeks, including a
      screening period up to 5 days, and 12-week follow-up after the injection.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision due to low subject recruitment and enrollment
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale [PI-NRS]</measure>
    <time_frame>baseline and 4 weeks after injection</time_frame>
    <description>The baseline value was defined as the average of PI-NRS values obtained at screening and at randomization visit.
The Week 4 value was defined as the average of PI-NRS values obtained daily through e-Diary assessments during Week 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in pain intensity as assessed by PI-NRS</measure>
    <time_frame>baseline and every other weeks up to 12 weeks after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pain-free days (score &quot;0&quot; pain on PI-NRS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days with rescue analgesia use</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of Life Questionnaire of the European Foundation for Osteoporosis [QUALEFFO] score</measure>
    <time_frame>baseline and 4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Short Form-12 Item Quality of Life Questionnaire [SF-12] score</measure>
    <time_frame>baseline and 4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change [PGIC] score</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 30% and 50% reduction from baseline in pain intensity</measure>
    <time_frame>up to 12 weeks after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: REGN475/SAR164877 serum concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Back Pain</condition>
  <arm_group>
    <arm_group_label>REGN475/SAR164877</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN475/SAR164877, single injection, dose depending on the participant's body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for REGN475/SAR164877), single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN475/SAR164877</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes</description>
    <arm_group_label>REGN475/SAR164877</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for REGN475/SAR164877)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Moderate to severe pain due to non-traumatic vertebral fracture associated with
        osteoporosis.

        Exclusion criteria:

          -  Mild pain score on the Pain Intensity-Numeric Rating Scale [PI-NRS] at screening and
             randomization visits;

          -  Narcotic addiction;

          -  Post-fracture vertebral instability;

          -  Unwillingness to use study-defined rescue analgesia exclusively.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840005</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840001</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840017</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840028</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840008</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840013</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840047</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840034</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840026</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840044</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840023</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <disposition_first_submitted>October 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 30, 2012</disposition_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

